Alprazolam / Propranolol Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.25mg + 20mg
Reference Brands: Beta Anxit (india)
Category:
Antipsychotropic Drugs
ALPRAZOLAM+PROPRANOLOL is used to treat anxiety disorder. Alprazolam is a benzodiazepine that increases the action of a chemical messenger called GABA, this helps suppress the nerve cell's excessive and abnormal activity in the brain.
Alprazolam / Propranolol Tablet is available in Tablets
and strengths such as 0.25mg + 20mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Alprazolam / Propranolol Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Alprazolam / Propranolol Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
A 6-week double-blind, controlled clinical study was conducted to evaluate the efficacy of propranolol hydrochloride and alprazolam in patients diagnosed with agoraphobia with panic disorder or panic disorder with or without limited phobic avoidance. The study included 29 patients, where 14 patients received alprazolam at a mean daily dose of 5.0 ± 2.3 mg, while 15 patients were treated with propranolol at a mean daily dose of 182.0 ± 60.5 mg.
The findings demonstrated that both alprazolam and propranolol were effective in suppressing panic attacks and reducing avoidance behavior associated with these conditions. Alprazolam, a benzodiazepine, showed a more rapid onset of its panicolytic effect, providing quicker symptomatic relief. Propranolol, a non-selective beta-blocker, also contributed to the management of physical symptoms related to anxiety and panic, such as palpitations and tremors.
Although alprazolam demonstrated faster action, propranolol showed promising results and may serve as a useful therapeutic option, particularly in patients where control of somatic symptoms is required. The study suggests that propranolol warrants further clinical evaluation to better define its role in the treatment of panic-related disorders.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing